In patients with moderate-to-severe plaque psoriasis , the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo , but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly .